Welcome to LookChem.com Sign In|Join Free
  • or
4-[(PHENYLSULFANYL)METHYL]BENZALDEHYDE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

496965-13-0

Post Buying Request

496965-13-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

496965-13-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 496965-13-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,9,6,9,6 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 496965-13:
(8*4)+(7*9)+(6*6)+(5*9)+(4*6)+(3*5)+(2*1)+(1*3)=220
220 % 10 = 0
So 496965-13-0 is a valid CAS Registry Number.

496965-13-0Upstream product

496965-13-0Downstream Products

496965-13-0Relevant academic research and scientific papers

Design and synthesis of long acting inhaled corticosteroids for the treatment of asthma

Millan, David S.,Ballard, Stephen A.,Chunn, Sara,Dybowski, Joseph A.,Fulton, Craig K.,Glossop, Paul A.,Guillabert, Edouard,Hewson, Christopher A.,Jones, Rhys M.,Lamb, David J.,Napier, Carolyn M.,Payne-Cook, Toby A.,Renery, Emmanuelle R.,Selby, Matthew D.,Tutt, Michelle F.,Yeadon, Michael

body text, p. 5826 - 5830 (2011/10/18)

In this Letter we present data for a novel series of ICS for the treatment of asthma. 'Inhalation by design' principles have been applied to a series of highly potent steroidal GR agonists, with a focus on optimising the potential therapeutic index in human. Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimise systemic exposure and reduce systemically driven adverse events. High CYP mediated clearance as well as glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimise drug-drug interactions. Furthermore, pharmaceutical properties such as stability, crystallinity and solubility were considered to ensure compatibility with a dry powder inhaler. This work culminated in the identification of the clinical candidate 15, which demonstrates preclinically the desired efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of asthma.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 496965-13-0